A PYMNTS Company

US: Pharmaceutical joint venture runs ahead without objection

By  |  August 14, 2013

Biotechnology firm Amgen announced a joint venture with pharmaceutical company Servier in a deal that gives Amgen the rights to heart drug ivabradine, approved in Europe, in the US. In return, Servier gained EU commercialization rights to a drug developed by Amgen, which has reached phase II testing in the US. The waiting period for antitrust regulators to review the deal has passed, say reports. Under terms of the joint venture, Amgen has the rights to chronic heart failure drug ivabradine, under the brand name in Europe of Procorain and will pay Servier $50 million for the rights. Additional financial details were not disclosed.

Full Content: PharmaTimes

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.